The stock of Cambrex Corporation (NYSE:CBM) is a huge mover today! About 623,777 shares traded hands or 96.90% up from the average. Cambrex Corporation (NYSE:CBM) has declined 12.62% since April 4, 2016 and is downtrending. It has underperformed by 13.71% the S&P500.
The move comes after 7 months positive chart setup for the $1.46 billion company. It was reported on Nov, 4 by Barchart.com. We have $65.07 PT which if reached, will make NYSE:CBM worth $627.80M more.
Cambrex Corporation (NYSE:CBM) Ratings Coverage
Out of 3 analysts covering Cambrex Corp (NYSE:CBM), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cambrex Corp has been the topic of 3 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Singular Research given on Thursday, February 11. The firm has “Overweight” rating by Stephens given on Tuesday, July 21.
According to Zacks Investment Research, “Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance enhancers; and polymer systems.”
Insitutional Activity: The institutional sentiment increased to 1.03 in Q2 2016. Its up 0.34, from 0.69 in 2016Q1. The ratio improved, as 22 funds sold all Cambrex Corporation shares owned while 76 reduced positions. 31 funds bought stakes while 70 increased positions. They now own 28.84 million shares or 4.08% less from 30.07 million shares in 2016Q1.
Tci Wealth has invested 0% of its portfolio in Cambrex Corporation (NYSE:CBM). Blair William And Il reported 17,301 shares or 0.01% of all its holdings. Friess Lc holds 0.07% of its portfolio in Cambrex Corporation (NYSE:CBM) for 12,790 shares. Concorde Asset Mgmt Limited Liability holds 4,800 shares or 0.25% of its portfolio. Tealwood Asset Management Incorporated reported 44,385 shares or 1.03% of all its holdings. Vanguard Gru Inc last reported 0.01% of its portfolio in the stock. Thompson Davis Company, a Virginia-based fund reported 1,001 shares. Renaissance Ltd Limited Liability Company has 0% invested in the company for 34,300 shares. Bnp Paribas Arbitrage Sa owns 10,385 shares or 0% of their US portfolio. Moreover, Wells Fargo & Mn has 0.03% invested in Cambrex Corporation (NYSE:CBM) for 1.67 million shares. Diam Comm has 80,075 shares for 0.06% of their US portfolio. State Board Of Administration Of Florida Retirement Systems has 44,337 shares for 0.01% of their US portfolio. Redwood Investments Limited Liability Corporation reported 104,999 shares or 0.5% of all its holdings. Moreover, Jpmorgan Chase And Com has 0% invested in Cambrex Corporation (NYSE:CBM) for 82,223 shares. Alphaone Investment Service Ltd Co, a Pennsylvania-based fund reported 66,548 shares.
Insider Transactions: Since May 9, 2016, the stock had 0 insider purchases, and 3 selling transactions for $1.09 million net activity. The insider KLOSK STEVEN M sold $686,245. KORB WILLIAM B sold $188,100 worth of Cambrex Corporation (NYSE:CBM) on Monday, July 11.
More notable recent Cambrex Corporation (NYSE:CBM) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on November 12, 2010, also Globenewswire.com with their article: “Cambrex Opens New Pilot Plant at Its Milan, Italy Site” published on October 03, 2016, Globenewswire.com published: “Claes Glassell Appointed to the Board of Directors of Cambrex Corporation” on March 16, 2016. More interesting news about Cambrex Corporation (NYSE:CBM) were released by: Seekingalpha.com and their article: “Cambrex Corporation: Exciting Time Ahead For This Biotech Company” published on March 24, 2016 as well as Streetinsider.com‘s news article titled: “Cambrex Corp. (CBM) to Acquire Privately-Held PharmaCore for ~$25M” with publication date: September 26, 2016.
CBM Company Profile
Cambrex Corporation (Cambrex), incorporated on October 11, 1983, is a life sciences company. The Firm provides services and products for the development and commercialization of new and generic therapeutics. The Firm supplies its services and products across the world to generic pharmaceutical companies. Cambrex operates through three divisions, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.